{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-099422","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.451617+00:00","generated_at":"2026-05-15T16:57:18.339362+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"confidence":"high","headline":"ImageneBio reports Q4 2025 net loss $6.9M; cash $135.3M; Phase 2b ADAPTIVE on track for 2027","bullets":["Cash, equivalents and marketable securities: $135.3M at Dec 31, 2025 vs $12.1M at Dec 31, 2024, after merger and $75M private placement.","Net loss Q4 2025: $6.9M vs $4.8M Q4 2024, driven by post-merger operating costs and transaction expenses.","Phase 2b ADAPTIVE trial (IMG-007 in atopic dermatitis) enrolling on schedule; blinded safety review found no pyrexia/chills/ulcers/malignancies.","Appointed Dr. Ben Porter-Brown as CMO in Feb 2026; also added CEO, CSO, CTO, and an independent director during 2025.","Submitted protocol amendment to expand dosing regimens, evaluate loading doses, and test patient-friendly intervals in ADAPTIVE."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-099422","json":"https://secwatch.observer/filing/0001193125-26-099422.json","markdown":"https://secwatch.observer/filing/0001193125-26-099422.md","text":"https://secwatch.observer/filing/0001193125-26-099422.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000119312526099422/0001193125-26-099422-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000119312526099422/d130344d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T16:57:18.339362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}